Similarly, a randomized phase III clinical trial including 119 melanoma patients revealed that RAF1 amplification elevated the efficacy of carboplatin and paclitaxel with sorafenib (CPS) in terms of progression-free survival (PFS) compared with carboplatin and paclitaxel treatment alone (CP) (HR, 0.372; P = 0.025) [152]. This evidence concerns the gene RAF1 and melanoma.